Health care industry
Hims & Hers faces scrutiny from senators on Super Bowl ad that ‘risks misleading’ patients
Hims & Hers is facing scrutiny from lawmakers over an advertisement for its weight loss offerings that’s slated to run during the Super Bowl on Sunday. Sens. Dick Durbin, D-Ill., and Roger Marshall, R-Kan., wrote a letter to the U.S. Food and Drug Administration on Friday expressing concerns over an “upcoming advertisement” that “risks misleading […]
Read More
Doximity shares pop 30% on revenue beat, rosy guidance
Piotr Swat | Lightrocket | Getty Images Doximity shares ripped more than 30% higher on Friday, a day after the company reported fiscal third-quarter results that beat Wall Street’s expectations for revenue and guidance. Doximity is a digital platform for medical professionals that can help them carry out telehealth appointments with patients, find referrals, stay […]
Read More
Alphabet’s Verily to sell Granular insurance business to Elevance Health
Verily headquarters in San Bruno, California. Courtesy: Verily Verily is selling its stop-loss insurance subsidiary, Granular Insurance Company, to the insurance provider Elevance Health, the Alphabet health tech company confirmed to CNBC on Thursday. Verily is one of Google’s sister companies and operates within Alphabet’s “Other Bets” category. The Granular sale is the latest in […]
Read More
Doximity shares soar 21% after company beats on revenue, raises fiscal-year guidance
Doximity at the New York Stock Exchange for its initial public offering on June 24, 2021. Source: NYSE Shares of Doximity popped 21% on Thursday after the company reported third-quarter fiscal 2025 results that beat analysts’ expectations for revenue and offered rosy guidance. Here’s how the company did: Earnings per share: 37 cents, may not […]
Read More
Bristol Myers’ stock decline in response to weak guidance is a gift to investors
Bristol Myers Squibb on Thursday reported better-than-expected quarterly results, but weak guidance for 2025 sent shares lower. Jim Cramer’s faith in the drugmaker is unshaken. Revenue in the fourth quarter rose 8% year over year to $12.34 billion, well ahead of the $11.57 billion consensus, according to analysts’ estimates compiled by LSEG. Adjusted earnings per […]
Read More
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024. Ore Huiying | Bloomberg | Getty Images Eli Lilly on Thursday said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a […]
Read More
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb on Thursday said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost savings effort to chart a path toward long-term […]
Read More
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
The Lilly Biotechnology Center in San Diego, California, on March 1, 2023. Mike Blake | Reuters Eli Lilly on Thursday reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but it saw lower realized prices. The figures were consistent with the preliminary results Eli Lilly shared […]
Read More
Novo Nordisk CEO says he’s confident about Wegovy supply, next-generation weight loss drugs
It’s been a rocky few months for Novo Nordisk. Prescription data from IQVIA suggests Novo’s obesity drug Wegovy is losing ground to rival Zepbound from Eli Lilly. Wegovy’s potential successor, CagriSema, came up short of investor expectations in a closely watched Phase 3 trial. Novo’s stock has fallen more than 20% over the last year, […]
Read More
Teladoc Health to acquire Catapult Health in $65 million deal
Pavlo Gonchar | Lightrocket | Getty Images Teladoc Health on Wednesday announced it will acquire the preventative care company Catapult Health in an all-cash deal for $65 million. Catapult offers an at-home wellness exam that allows members to check their blood pressure, collect a blood sample, log other screening information and meet virtually with a […]
Read More